A small-scale study on mice has demonstrated that a mucosal DNA vaccine can effectively pause COVID-19 in its tracks. The study revealed that the vaccine can ensure the complete survival of a group of mice infected with a variant adjusted to this species. Its function is similar to the commercially available RNA vaccines and is created using a vector developed by a CNRS* researcher at Nantes University, France. The vaccine uses a synthetic nanoparticle vector , which enables easy passage through mucous membranes to introduce the viral protein-encoded DNA into the respiratory cells.
The vector’s DNA enters the target cells, activating them to produce SARS-CoV-2 protein and triggering the immune system to produce antibodies against the virus. According to the study, vaccinations through mucous membranes offer successful protection against SARS-CoV-2 infections. Also, immune cells in the…
